CLINICAL RESEARCH
Year : 2013 | Volume
: 34 | Issue : 4 | Page : 339--345
Assessment of Lekhana Basti in the management of hyperlipidemia
Swapnil S Auti1, Anup B Thakar2, Vinay J Shukla3, B Ravishankar4
1 Ph.D. Scholar, Department of Panchakarma, Gujarat Ayurved University, Jamnagar, Gujarat, India
2 Associate Professor and I/C Head, Department of Panchakarma, Gujarat Ayurved University, Jamnagar, Gujarat, India
3 Head, Pharmaceutical Chemistry Laboratory, Institute For Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India
4 Director, Research and Development, S. D. M. College of Ayurveda Udupi, Karnataka, India
Correspondence Address:
Swapnil S Auti
B/16, Staff Colony, Gujarat Ayurved University, Jamnagar - 361 008, Gujarat
India
Hyperlipidemia is highly prevalent and is closely related to coronary heart disease which is the most common cause of death. Raised cholesterol is estimated to be responsible for 18% of cerebrovascular disease and 56% of ischemic heart disease. Overall, these diseases account for about 4.4 million deaths (7.9% of the total). Based upon the etiological factors and symptom complexes, hyperlipidemia can be considered as a part of Medoroga. Being a Tikshna formulation, the treatment modality of Lekhana Basti is aimed basically for Apatarpana (emaciation) of the body, as Basti is the fastest Apatarpana. In the present clinical trial, a total of 22 patients were registered of whom 19 patients completed the course of the therapy. Under randomization, the registered patients were divided into two groups of which group A was treated with Lekhana Basti and group B was administered standard control drug, i.e., Triphala Guggulu, for 21 days. The results of the study revealed that in patients treated with Lekhana Basti, there was a decrease of about 4.99% in S. cholesterol, 9.13% in S. low density lipoprotein (LDL), and 0.36% in S. apolipoprotein B. Lekhana Basti was found to have significant effect in reducing the symptoms of Medodushti and in reduction of objective parameters like weight, body mass index (BMI), body fat percentage, body circumferences such as chest, abdomen, hip, pelvis, mid-thigh circumference, etc., and skin fold thickness as biceps, triceps, mid-arm, and abdominal skinfold thickness.
How to cite this article:
Auti SS, Thakar AB, Shukla VJ, Ravishankar B. Assessment of Lekhana Basti in the management of hyperlipidemia.AYU 2013;34:339-345
|
How to cite this URL:
Auti SS, Thakar AB, Shukla VJ, Ravishankar B. Assessment of Lekhana Basti in the management of hyperlipidemia. AYU [serial online] 2013 [cited 2023 Mar 24 ];34:339-345
Available from: https://www.ayujournal.org/article.asp?issn=0974-8520;year=2013;volume=34;issue=4;spage=339;epage=345;aulast=Auti;type=0 |
|
